Table 2.
Tumour and treatment characteristics.
| Treatment setting | De novo metastatic | 226 (50%) |
| Locoregional recurrence | 37 (8%) | |
| Distant recurrence | 191 (42%) | |
| Others | 2 (1%) ➢ neoadjuvant (1) ➢ PD on neoadjuvant chemo (1) |
|
| Hormone sensitivity of patients with recurrent BC | Hormone resistant ➢ Recurred while on adjuvant hormone therapy ➢ Recurred ⩽ 12 months from end of adjuvant hormone therapy |
85 (37%) ➢ 67 (79%) ➢ 18 (21%) |
| Hormone sensitive ➢ Recurred 13–24 months from end of adjuvant endocrine therapy ➢ Recurred > 24 months from end of adjuvant endocrine therapy |
86 (38%) ➢ 8 (9%) ➢ 78 (91%) |
|
| Did not take endocrine therapy in adjuvant setting | 27 (12%) | |
| Unknown | 30 (13%) | |
| Histology | Invasive ductal carcinoma | 327 (72%) |
| Invasive lobular carcinoma | 34 (7%) | |
| Others ➢ Colloid ➢ Medullary ➢ Papillary ➢ Mucinous ➢ No special type |
46 (10%) ➢ 1 (2%) ➢ 1 (2%) ➢ 4 (9%) ➢ 12 (26%) ➢ 25 (54%) |
|
| Unknown | 49 (11%) | |
| Biomarker status | Oestrogen receptor ➢ Positive ➢ Negative ➢ Unknown |
448 (98%) 3 (1%) 5 (1%) |
| Progesterone receptor ➢ Positive ➢ Negative ➢ Unknown |
369 (81%) 72 (16%) 15 (3%) |
|
| Her2Neu ➢ Positive ➢ Negative |
17 (4%) 439 (96%) |
|
| Site of metastasis | Brain metastasis | 25 (5%) |
| Peritoneum | 31 (7%) | |
| Liver | 145 (32%) | |
| Lung | 244 (54%) | |
| Bone | 342 (75%) | |
| Type of CDK4/6 inhibitor | Palbociclib | 435 (95%) |
| Ribociclib | 21 (5%) | |
| Partner anti-oestrogen therapy with CDK4/6 inhibitor | Fulvestrant | 128 (28%) |
| Aromatase inhibitor ➢ Letrozole ➢ Anastrozole ➢ Exemestane |
290 (64%) ➢ 236 (81%) ➢ 16 (6%) ➢ 38 (13%) |
|
| Tamoxifen | 38 (8%) | |
| Line of treatment | First line | 122 (27%) |
| Second line | 119 (26%) | |
| Third line | 70 (15%) | |
| Fourth line and beyond | 145 (32%) |
BC, breast cancer; CDK4, CDK4/6i, cyclin-dependent kinase 4.